Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

FNMFO FNMFO JAPAF 096770 Restaurants Sport Products Apparel 
Benchmark  United States  NYSE  10,937   50.536 Index Moved Down -0.46%  

Processing. Please wait...

BIOLINE insider: Kinneret Savitsky


Kinneret Savitsky - BIOLINE Insider Profile

CEO, Director

Dr. Kinneret Savitsky serves as Chief Executive Officer and Director at BioLine Rx Ltd since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers
Age: 45  CEO Since 2010      
972 2 548 9100

Other Appointments

BioLineRx LtdBLNEFUnited States OTC
BioLineRx LtdBLRXUnited States Nasdaq
Kinneret Savitsky EducationSavitsky has a BS degree in Biology from The Hebrew University of Jerusalem, MS degree in Human Genetics and a PhD, with distinction, in the Department of Human Genetics, both from the TelAviv University.

Management Efficency

The company has return on total asset (ROA) of (39.95) % which means that it has lost $39.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (77.4) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 44.85 K in total debt. BIOLINE RX LTD has Current Ratio of 3.83 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Kinneret Savitsky Ph.D., 44Chief Exec. Officer327.00KN/AMr. Philip A. Serlin CPA, MBA, 51Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Member of Investment Monitoring Committee271.00KN/AProf. Moshe Phillip M.D., 57VP of Medical Affairs, Sr. Clinical Advisor and Member of Scientific Advisory Board291.00KN/ADr. Leah Klapper Ph.D., 47Gen. Mang. of BioLine Innovations Jerusalem237.00KN/A Raziel Fried, Treasurer and Member of Investment Monitoring CommitteeN/AN/ABIOLINE RX LTD [BLNEF] is traded on OTC Market in USA. It is located in , except where noted. and employs 52 people.

Filter other executives

Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
Showing first 16 of many records found

CEO Since

Nils AndersenAP M
Claus HemmingsenAP M
Christopher KirkSGS SA
Stephen BirdCitigroup Inc
Timothy MayopoulosFED NATL MTG PFD I
Timothy MayopoulosFederal National Mortgage Assoc
Barbara DesoerCitigroup Inc
James CowlesCitigroup Inc
Francisco SilvaCitigroup Inc
Soeren SkouAP M
James ForeseCitigroup Inc
Kim FejferAP M
Jakob ThomasenAP M
Michael CorbatCitigroup Inc
Morten EngelstoftAP M
William MillsCitigroup Inc
USA Stock
Currency: USD - US Dollar
Traded on OTC Market

Fix Your Portfolios with BIOLINE

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add BIOLINE RX LTD to your portfolio


Jacob Friedman, Director, MBA
Nurit Benjamini, Director, MBA
Raphael Hofstein, Director
Kinneret Savitsky, CEO
Aharon Schwartz, Chairman
Philip Serlin, COO
Moshe Phillip, President, Ph.D
Michael Anghel, Director, MBA
Leah Klapper, Executive
David Malek, President
Avraham Molcho, Director, MBA
Sandra Panem, Director, Ph.D

Stock Performance

Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities